Results 101 to 110 of about 16,532 (175)

The Use of Trichostatin A to Rescue TRKA+ Neurons in a Mouse Model of Familial Dysautonomia [PDF]

, 2017
Familial dysautonomia is a severe, recessive disease that devastates the peripheral nervous system, culminating in death of most patients by age 40.
Buksch, Richard
core  

Case Report GABA B Encephalitis: A Fifty-Two-Year-Old Man with Seizures, Dysautonomia, and Acute Heart Failure

, 2020
Autoantibodies to the -aminobutyric acid receptor, subtype B (GABA B ), are a known cause of limbic encephalitis. The spectrum of clinical manifestations attributable to this antibody is not well defined at the present time.
Kevin R Patel, Lindsey Wooliscroft, Matthew C Loftspring, Sally Jo, Eric Landsness, Robert Rudock   +5 more
core  

Cardiac dysautonomia in Huntington’s disease

, 2013
Huntington's disease is a fatal, hereditary, neurodegenerative disorder best known for its clinical triad of progressive motor impairment, cognitive deficits and psychiatric disturbances.
Shattock, Michael; id_orcid, Abildtrup, Mads   +1 more
core   +1 more source

Dysautonomia awareness month

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2022
Jamir Pitton Rissardo, Ana Leticia Fornari Caprara   +1 more
doaj   +1 more source

Prevalence of dysautonomia in chronic musculoskeletal pain: a cross-sectional study. [PDF]

Rheumatology (Oxford)
Almutairi NA, Greenwood DC, Sivan M.
europepmc   +1 more source

Small Fiber Neuropathy is Present in Nonpainful Conditions. [PDF]

Clin Med Res
Blitshteyn S.
europepmc   +1 more source

Autoimmune myasthenia gravis and dysautonomia in a dog

A two-year-old male entire border collie dog was evaluated for a short history of mixed bowel diarrhoea, coughing, vomiting and stranguria. Physical examination revealed dyspnoea with increased ventral lung sounds and a flaccidly distended bladder ...
Niessen, S J M, Shelton, G D, Cherubini, G B, Gajanayake, I   +3 more
core   +1 more source

Assessment of internal consistency reliability and concurrent validity of PROMIS^® Dyspnea Characteristics v1.0, PROMIS^® Dyspnea Functional Limitations 10a, and PROMIS^® Global Health v1.2 in a dysautonomia cohort. [PDF]

J Patient Rep Outcomes
Latham AJ, O'Dell JA, Ho T, Chavis S, Smith SE.   +4 more
europepmc   +1 more source

Improved outcomes for patients with autonomic movement disorders originally evaluated for psychogenic non-epileptiform spells. [PDF]

Front Neurol
Khoo A, Paul M, Rady N, Sunda M, Brik J, Vaou O, Hohler A.   +6 more
europepmc   +1 more source

Short-Course, Low-Dose Metoclopramide as Bridge Therapy for Dysautonomia-Associated Gastrointestinal Dysmotility in Adolescents: A Case Series. [PDF]

Children (Basel)
Wilder A, Morris C, Patel D, Setya A.
europepmc   +1 more source